The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.

Abstract

T cells genetically engineered to express tumour-targeting receptors are attractive anti-cancer therapeutic agents. Human T cells engrafted with a chimeric receptor specific for the B-cell lymphoma antigen CD19 fused to the CD3zeta receptor (aCD19z) are functional in vitro. Current successful clinical protocols targeting melanoma use pre-conditioning chemotherapy in combination with T cells. This study demonstrated that interleukin-2 expanded aCD19z T cells combined with cyclophosphamide effectively treated five-day established Raji B-cell lymphoma in an immunocompromised model system with 50% of mice surviving >100 days. This observation strongly supports the combination of antibody targeted T cells with chemotherapy as a novel approach for the therapy of CD19(+) B-cell malignancies.

• Authors: Eleanor J Cheadle, David E Gilham, Robert E Hawkins
• Journal: British journal of haematology (Br J Haematol) Vol. 142 Issue 1 Pg. 65-8 (Jul 2008) ISSN: 1365-2141 [Electronic] England
• PMID: 18477047 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, CD19
• Immunoconjugates
• Cyclophosphamide

Topics

• Animals
• Antigens, CD19 (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Genetic Engineering
• Genetic Vectors
• Immunoconjugates (administration & dosage)
• Lymphoma, B-Cell (therapy)
• Mice
• Mice, SCID
• T-Lymphocytes